Ted Lain, MD, MBA, a board-certified dermatologist at Sanova Dermatology in Austin, Texas, discusses the randomized phase 3 THRIVE-AA1 trial (NCT04518995), which assessed the safety and efficacy of deuruxolitinib (Leqselvi). The study included patients with severe alopecia, with 95% having a Severity of Alopecia Tool (SALT) score of 95 or higher. By Week 24, 29.6% of patients achieved a SALT score of 20. Statistical significance was observed as early as week 8 with deuruxolitinib compared to placebo, with a steady improvement slope. Dr. Lain noted that the safety data showed minimal adverse events, with no thrombosis, malignancies, or strokes, and a low incidence of gastrointestinal disorders.
- Overview of THRIVE-AA1 trial design and patient severity criteria
- Primary efficacy endpoint and proportion of patients achieving significant hair regrowth
- Time course of response and safety profile with an oral Janus kinase inhibitor
Explore Related Resources:
Use of Deuruxolitinib for Hair Regrowth in Patients With Alopecia Areata
Use of JAK Inhibitors for Alopecia Areata Treatment
